Manchester University NHS Foundation Trust gets NHS England's EONIS-Q work
- NHS England
- North West
- 3 bids
NHS England awarded Manchester University NHS Foundation Trust newborn screening lab work based on the EONIS-Q methodology.
The work feeds the NHS Newborn Blood Spot in-service evaluation for Severe Combined Immuno-Deficiency (SCID). Spinal Muscular Atrophy (SMA) is being added to that evaluation, as the UK NSC recommended. Lab capacity and turnaround have to keep pace alongside existing SCID testing. Specialist staff oversee quality and reporting, and data moves through secure flows for national evaluation.
The direct award, made in March 2026, covers three labs that use EONIS-Q. Its estimated value of £1.87m is not split between them. The contract runs for two years, with an optional third year that could take it to March 2029.
- What
- Screening and population testing programmes
- Buyer
- NHS England
- Value
- £1.87m
- How it was bought
- Not published
- 3 bids
- Dates and next
- 5 Mar 2026